Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

摘要: One-hundred fourteen patients with advanced testicular cancer were randomized to treatment consisting of either high-dose (120 mg/m2, monthly) or low-dose (15 daily X 5 cisplatin, both combined vinblastine and bleomycin. There 60 (53%) complete remissions 42 partial for an overall response rate 90%. An additional 11 patients, 4 carcinoma 7 mature teratoma, following surgical cytoreduction, rendered free disease. was a significantly higher high dose induction chemotherapy, 63%, when compared low dose, 43% (P = 0.03). A survival advantage also observed receiving therapy 0.009). For the subgroup maximal disease embryonal ± teratoma seminoma histology there clear in favor over have been only four relapses, all occurring within 1 year study entry. While has frequency leukopenia, renal, neuromuscular, mucosal toxicity therapy, thus far no irreversable leading functional impairment seen. The authors demonstrated clear-cut relationship not survival, but increased potential cure as well. Cancer 53:1029-1035, 1984.